Principia Biopharma shot up due to swirling rumors regarding Sanofi's interest in the firm, Avisol Capital Partners noted on the Seeking Alpha blog last Friday. 20 July 2020
As Taiho Oncology, a US subsidiary of Japan’s Taiho Pharmaceutical, continues to add early- and late-stage assets to its expanding oncology portfolio, the company today announced the hiring of Dr Stephen Yoder, as vice president, business development, effective June 15, 2020. 15 July 2020
Following the launch of the AMR Action Fund, Brighton, UK-based Destiny Pharma has commented on the urgent need for such resources to combat the rise of antimicrobial resistance. 15 July 2020
Final results have been presented from the PUPs A-LONG and PUPs B-LONG studies assessing Elocta (efmoroctocog alfa) and Alprolix (eftrenonacog alfa) in previously untreated patients (PUPs) with hemophilia A and B, respectively. 14 July 2020
Revitope Oncology and Junshi Biosciences have inked a strategic research collaboration based around Revitope’s protein engineering platform and Junshi's novel antibody components. 14 July 2020
US biotech giant Amgen has announced an additional investment of approximately $421 million in BeiGene's registered direct offering of ordinary shares, which maintains Amgen's current pro rata ownership of BeiGene at approximately 20.3%. 13 July 2020
Shanghai-based Ocumension Therapeutics has raised $184 million through an Initial Public Offering (IPO), listing on the Hong Kong Stock Exchange. 10 July 2020
The US regulator will review a submission from LEO Pharma for approval to market tralokinumab in moderate-to-severe atopic dermatitis (AD). A target action date has been set for the second quarter of 2021. 9 July 2020
Chinese drugmaker and distributor Jiangsu Hengrui Medicine's subsidiary in Shanghai and Hengrui's chairman Sun Piaoyang have formed a new biotech company - Rui Li Di – based in Shanghai. 7 July 2020
US CNS-focussed drug developer Amylyx Pharmaceuticals today announced it has closed an oversubscribed $30 million Series B financing, led by Morningside Ventures, with participation from other investors. 1 July 2020
Sumitomo Dainippon Pharma Oncology Inc has been formed today through the merger of Tolero Pharmaceuticals and Boston Biomedical, two clinical-stage companies developing novel cancer therapeutics based in the USA and wholly-owned subsidiaries of Japanese drug major Sumitomo Dainippon Pharma. 1 July 2020
The rare diseases business of Italy’s Chiesi has inked a deal with USA-based Bioasis Technologies, related to the latter’s “xB3” platform. 30 June 2020
Swedish Orphan Biovitrum (Sobi) has negotiated a deal with the UK’s National Health Service (NHS), resulting in greater access to Elocta (efmoroctocog alfa) for people with hemophilia A. 26 June 2020
Japan’s largest drugmaker Takeda Pharmaceutical says the US Food and Drug Administration has approved the company’s submission for its biologics manufacturing facility located in Brooklyn Park, Minnesota for the production of Entyvio (vedolizumab) drug substance. 24 June 2020
Privately-held Plakous Therapeutics has been granted orphan drug and rare pediatric disease designations for its human placental extract, Protego-PD, for the prevention of necrotizing enterocolitis (NEC) in early preterm infants. 19 June 2020
Teva Pharmaceutical Industries has presented new data on quality of life measures among patients treated with Ajovy (fremanezumab-vfrm) during the 12-week open-label extension of the Phase IIIb FOCUS study. 18 June 2020
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024